Rakuten   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2015
NCT02422979
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Aspyrian Therapeutics, Inc. | Rakuten Aspyrian, Inc. | Rakuten Medical, Inc.

Active Ingredients

Drugs in Phase 3 Trials (5)

asp-1929 (3 trials)

cetuximab (erbitux) (1 trial)

docetaxel (taxotere) (1 trial)

methotrexate (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 2 Trials (3)

cemiplimab (libtayo) (1 trial)

pembrolizumab (keytruda) (2 trials)

rm-1929 (1 trial)

Drugs in Phase 1 Trials (1)

rm-1995 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Squamous Cell (Phase 2)

Head and Neck Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 9